论文部分内容阅读
目的:分析布地奈德与沙丁胺醇雾化吸入治疗支气管哮喘急性发作的临床疗效。方法:回顾性分析2012年6月~2013年6月期间在我院治疗的64例支气管哮喘急性发作患者的临床资料。将64例患者随机分为治疗组和对照组各32例,治疗组给予布地奈德与沙丁胺醇联合雾化吸入治疗,对照组仅给予沙丁胺醇雾化吸入治疗,观察两组临床疗效及不良反应。结果:治疗组总有效率为96.88%,对照组总有效率为84.37%,两组差异有统计学意义(P<0.05);治疗组FEV1、FVC和PEF均显著高于对照组(P<0.05)。结论:布地奈德与沙丁胺醇雾化吸入治疗支气管哮喘急性发作疗效显著,安全性好,值得临床推广应用。
OBJECTIVE: To analyze the clinical efficacy of budesonide and salbutamol inhalation in the treatment of acute exacerbation of bronchial asthma. Methods: The clinical data of 64 patients with acute exacerbation of bronchial asthma treated in our hospital from June 2012 to June 2013 were retrospectively analyzed. Sixty-four patients were randomly divided into treatment group and control group, with 32 cases in each group. The treatment group was treated with budesonide combined with albuterol inhalation. The control group was treated with salbutamol inhalation alone. The clinical efficacy and adverse reactions were observed in both groups. Results: The total effective rate was 96.88% in the treatment group and 84.37% in the control group, with significant difference between the two groups (P <0.05). The FEV1, FVC and PEF in the treatment group were significantly higher than those in the control group (P <0.05) ). Conclusion: The efficacy of budesonide and salbutamol nebulized inhalation in the treatment of acute exacerbation of bronchial asthma is significant, safe and worthy of clinical application.